Tuesday
August
04
2015
12:29 am
Weather

  Home
  Local News
  State / National / World
  Sports
  Opinion / Letters
  Business
  Arts / Entertainment
  Lifestyle
  Obituaries
  Calendar
  Submit Event
  Comics / Games
  Classifieds
  DJ Designers
  Archives
  Advertise With Us
  About Us
 
 
 
 
Allergan to sell Lap-Band unit for $75M in cash
October 30, 2013, 05:00 AM The Associated Press

IRVINE — Cosmetic drug and device maker Allergan Inc. reported better-than-expected earnings Wednesday and announced it is selling its Lap-Band gastric bypass business.

Apollo Endosurgery will give Allergan an upfront payment of $75 million in cash plus a $15 million stake in the company in return for rights to the device, which is a stomach-restricting band used to treat obesity. The deal, which is expected to close this year, also includes up to $20 million in additional payments to Allergan based on various business milestones.

Analysts had high hopes for Allergan’s Lap-Band business, in part because more than a third of American adults are obese. In 2011, Allergan won regulatory approval to expand marketing for Lap-Band to a much wider group of obese patients in the U.S., but demand for the device never met expectations. The stomach-restricting band limits food intake, but can also cause irritation of the esophagus, infection, nausea and vomiting in some cases.

Allergan said its net income rose to $299.8 million, or $1 per share, up from $249.4 million, or 82 cents per share, in the prior year period. When adjusted for one-time events and charges the company would have earned $1.23 per share.

Sales increased 13 percent to $1.56 billion in the quarter. Sales of Botox increased 12.5 percent to $486 million. Last month Allergan won U.S. approval to market the botulin-based injection for a new use to treat crow’s feet, or wrinkles that form on the outside edge of the eyes. The drug is approved for a half-dozen other uses, most famously forehead wrinkles, but also migraines and overactive bladder.

Sales of medical devices, including breast implants, increased 13.4 percent to $198.6 million.

Analysts polled by FactSet expected earnings per share of $1.21 on sales of $1.53 billion.

For the fourth quarter Allergan said it expects earnings per share between $1.31 and $1.33. That’s slightly below the most recent estimate by analysts for $1.35 per share.

Shares of Allergan Inc. fell $1.10, or 1.2 percent, to $92.28 in midday trading. Its shares are up 1 percent from the start of the year.

 

 

Tags: allergan, million, share, percent, sales, device,


Other stories from today:

 

 
Print this Page Print this Page  |  Bookmark and Share
<< Back
 
Return To Archives
 
  


 
 
 
Daily Journal Quick Poll
 
If the state of California had extra water, who or what should get it first?

Farmers
Natural habitat
Urban areas
Reservoirs
Don't know

 

 
 
 
 
 
 
 
Obama heralds impact of power plant greenhouse gas limits
WASHINGTON — Calling it a moral obligation, President Barack Obama unveiled the final version of h..
Weather helps crews battling massive California wildfire
LOWER LAKE, Calif. — Cooler, wetter weather helped crews make inroads Monday against a massive Nor..
US auto sales strong in July on SUV, luxury demand
DETROIT — Summer deals and big demand for SUVs and luxury vehicles kept U.S. auto sales strong in ..
Former trader given 14 years prison for market manipulation
LONDON — A British judge sentenced a former Citibank and UBS trader to 14 years in prison Monday a..
Sen. Schumer, comedian Amy Schumer call for more gun control
NEW YORK — Stand-up comedian and actress Amy Schumer is teaming up with New York Sen. Charles Schu..
More >>  
 
 
  
 
  
 
©2015 San Mateo Daily Journal
San Mateo County events